Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Cash & Equivalents (2020 - 2025)

SOPHiA GENETICS's Cash & Equivalents history spans 6 years, with the latest figure at $70.3 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 42.97% to $70.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $70.3 million, a 42.97% decrease, with the full-year FY2025 number at $70.3 million, down 42.97% from a year prior.
  • Cash & Equivalents hit $70.3 million in Q4 2025 for SOPHiA GENETICS, down from $81.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for SOPH hit a ceiling of $210.0 million in Q3 2021 and a floor of $42.5 million in Q2 2021.
  • Historically, Cash & Equivalents has averaged $126.5 million across 5 years, with a median of $128.0 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: crashed 45.17% in 2021 and later surged 321.07% in 2022.
  • Tracing SOPH's Cash & Equivalents over 5 years: stood at $193.0 million in 2021, then fell by 16.41% to $161.3 million in 2022, then changed by 0.0% to $161.3 million in 2023, then fell by 23.59% to $123.3 million in 2024, then plummeted by 42.97% to $70.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for SOPH at $70.3 million in Q4 2025, $81.6 million in Q3 2025, and $94.8 million in Q2 2025.